The obesity-drug race is no longer only about who can produce the most weight loss. Convenience, tolerability, and keeping patients on treatment may become just as important. One clinical-stage biotech just showed that its lead drug could potentially maintain most of its benefit with injections as infrequent as once a month.
Next Gold Mover (Sponsored)
What Elon is doing in AI is exactly what he’s done his entire career.
He took over mobile payments with PayPal. Electric cars with Tesla. Commercial space launches with SpaceX.
Now he’s doing it with Artificial Intelligence… and James Altucher believes we could see as many as 1.8 MILLION new “Musk millionaires” over the next decade from his impending AI takeover.
According to James Altucher, there’s one company sitting at the dead center of his plan… and it's still trading for less than $100.
James compiled all the critical details you need to position yourself early in this FREE Millionaire Maker Masterclass.
VIEW IT NOW
What Just Happened
Viking Therapeutics, Inc. (NASDAQ: VKTX) reported positive results from a 33-week study of VK2735, its experimental dual GLP-1/GIP obesity treatment.
Patients first received weekly injections for 21 weeks, producing average weight loss of roughly 16% to 19%, with no plateau. Participants then switched to less frequent maintenance schedules for another 12 weeks.
The strongest every-other-week group preserved 97% of the weight lost during the initial treatment period. The best monthly group preserved 90%. Patients switched to placebo maintained only 61%.
An exploratory group that stayed on weekly 17.5 mg dosing reached 21.7% average weight loss after 33 weeks, again with no plateau.
That combination sent the shares sharply higher because it suggests VK2735 may offer more flexibility than the standard once-weekly GLP-1 model.
Why Maintenance Could Matter So Much
Obesity treatment is increasingly looking like long-term therapy rather than a short course of medication. That creates a major problem: weekly injections can become inconvenient, expensive, and difficult to sustain over many years.
A maintenance schedule requiring only one or two injections per month could change the economics for both patients and healthcare systems.
Someone might use weekly treatment while actively losing weight, then transition to lower or less frequent maintenance dosing once they reach their goal. Fewer doses could reduce drug usage, potentially lower treatment costs, and make adherence easier.
The latest study also showed encouraging tolerability. Gastrointestinal side effects during maintenance were broadly similar to placebo, and treatment discontinuations remained low.
This does not prove monthly VK2735 will eventually become the standard maintenance option. The study included only about 180 adults and needs confirmation in larger trials. But the data give Viking another potential differentiator in an increasingly crowded market.
Phase 3 Is Already Underway
Viking is not waiting for these results to begin late-stage development.
Its VANQUISH-1 and VANQUISH-2 Phase 3 trials for injectable VK2735 are fully enrolled. Together they include roughly 5,500 participants, with treatment lasting 78 weeks.
VANQUISH-1 is studying adults with obesity, while VANQUISH-2 focuses on patients with obesity and type 2 diabetes. The primary endpoint is the percentage change in body weight versus placebo.
That gives you a much larger dataset ahead that will ultimately matter more than the maintenance study.
The important point is that VK2735 has already progressed beyond the earlier-stage biotech story. Viking now has a lead asset deep into Phase 3 with encouraging data across several different studies.
The Oral Version Adds Another Option
Viking is developing the same drug as a daily tablet.
Earlier Phase 2 results showed up to 12.2% average weight loss after just 13 weeks of oral treatment, with as many as 80% of patients in certain groups losing at least 10% of body weight.
The company expects to begin Phase 3 testing of oral VK2735 during the fourth quarter.
If both formulations ultimately succeed, Viking could offer patients several ways to use the same underlying drug: a tablet, weekly injections, or potentially less frequent maintenance injections.
That flexibility could matter in a market where patients have very different preferences around needles, pills, side effects, and long-term treatment.
Rating System (Sponsored)
A Bloomberg Terminal costs about $32,000 a year.
But this stock rating system gives everyday investors powerful market intelligence for a fraction of that price.
According to The Wall Street Journal, it outperformed every firm reviewed.
Its “Buy” ratings have averaged a 303% gain, including winners and losers.
Get full access to the stock rating system here.
The Market Opportunity Is Huge, But So Is The Competition
The global obesity-drug market could eventually reach roughly $100 billion in annual sales. That explains why almost every large pharmaceutical company wants a piece of it.
Eli Lilly and Novo Nordisk already dominate. Roche, Amgen, Pfizer, AstraZeneca, Merck, and several smaller biotech companies are pushing new injectable and oral treatments through development.
Viking therefore does not simply need a drug that works.
It needs a product differentiated enough to compete against companies with enormous manufacturing capacity, established physician relationships, and global commercial organizations.
Monthly maintenance and the ability to offer both oral and injectable formulations could help. But those advantages still need to survive Phase 3 and regulatory review.
Cash Is The Other Big Question
Viking ended June with about $502 million in cash and investments, but clinical development is expensive. Research and development spending reached $115.8 million during Q2, nearly double the year-ago level.
The company responded to this week's rally by announcing plans to raise $200 million through common stock and another $200 million through convertible notes.
That strengthens the runway for Phase 3 development and eventual commercialization, but it also creates dilution risk.
This is a reminder that Viking remains a clinical-stage biotech with no approved product generating cash. Strong trial data can increase the value of the pipeline, but shareholders still fund much of the journey to market.
Elite Trade Club Insider
A CEO Bought $4.6 Million While A Major Holder Sold $453 Million In Eight Days
You’re looking at one payments platform still growing revenue near 30% and one shipping company enjoying the strongest quarter in its history. Elite Trade Club Insider readers are seeing very different reactions to those results: one co-founder just put $4.61 million of fresh capital into his stock, while a major shareholder has sold roughly $453 million in little more than a week.
You’re reading the free version. Here’s what we held back.
Every day, insiders and institutions move millions before the market catches on. We surface the data behind those moves before the rest of the market sees it.
A subscription gets you:
The insider buys, options bets, and dark pool moves the free edition can't show you. Unlocked every weekday.
A Sunday Deep Dive that tells you where to look before Monday's bell rings.
The Friday Smart Money Brief: who bought, who sold, where the big options bets landed, and where institutions are hiding volume. Three data layers. One email.
A Monthly Insider Scorecard so you always know whether smart money is buying or selling the market.
Every past Insider edition, unlocked, on elitetrade.club. Go back and see what you missed.
$25/mo or $250/yr. 30-day money back guarantee. Cancel anytime. Founding member pricing: lock in $25/mo before we raise it.
What Could Trip It Up
The biggest risk is clinical. Encouraging Phase 2 and maintenance data do not guarantee Phase 3 success, regulatory approval, or commercial adoption.
Competition is another major issue. The obesity market may be enormous, but the number of credible drugs entering development keeps growing.
Finally, dilution will remain part of the story until Viking generates meaningful revenue or signs a major partnership.
Power Catalyst (Sponsored)
In 2022, one man identified Rolls-Royce below $2 before shares later climbed above $10.
Now he says he’s seeing similar fingerprints in another company: billions in operating income, rapid growth, a low valuation and a powerful AI-energy catalyst.
Click here to learn more
My Take
Buy on pullbacks, but treat this as a speculative biotech position. VK2735 now has compelling weekly weight-loss data, encouraging monthly and every-other-week maintenance results, fully enrolled Phase 3 injectable trials, and an oral program approaching Phase 3.
The key risk is that the stock is still being valued on future clinical success. I would not chase the immediate data-driven rally. Use volatility to build gradually and keep the position smaller than you would for an established profitable company.
Action Recap
💉 Looking to buy? Buy on pullbacks and keep the position measured.
📈 Already own it? Hold while Phase 3 development stays on track and oral VK2735 advances.
⚠️ Main risk to respect: Great mid-stage data still has to survive Phase 3, regulation, and intense competition.
You Read This Far. Here's Where the Real Work Lives.
We run three live portfolios on Autopilot, and everything about them is public: every position, every allocation, every trade, visible the moment it happens.
We keep our own money in each one, because analysis you won't fund yourself is just content.
THE UNBREAKABLE STACK
Our growth book: durable software and cybersecurity names built to compound quietly for years.
THE HORMUZ PREMIUM
Our energy thesis: built for how that sector actually pays, over quarters, not headlines.
THE SQUEEZE
The defensive sleeve: staples and steady compounders, boring on purpose, built for the nights you'd rather sleep than watch futures.
And here's the part that makes it effortless: Autopilot does the trading for you. Connect the brokerage you already use (Robinhood, Schwab, Fidelity, and more) and every move we make gets mirrored in your own account automatically.
Your money never leaves your brokerage. It stays in your account, under your control, and you can override any trade or disconnect anytime. Autopilot even rebalances automatically when allocations drift, and you get a notification every time something happens.
No watching tickers. No timing entries. No fat-finger mistakes at market open. You pick the portfolio, we do the work, your account follows along.
Pick the one that fits your risk level, or run all three:
Live portfolios, real positions, our own capital at stake. Your funds stay in your own brokerage account. Past performance doesn't guarantee future results.
That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.
Best Regards,
— Adam Garcia
Elite Trade Club
Click here to get our daily newsletter straight to your cell for free.
P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.
